Product/Composition:- | Lincomycin Oral Capsules/Tablets |
---|---|
Strength:- | 250mg, 500 mg |
Form:- | Oral Capsules/Tablets |
Reference Brands:- | Lincocin (US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide elongation. It effectively treats severe Gram-positive infections, such as skin and soft tissue infections. Benefits include rapid bacterial eradication, high efficacy against resistant strains, and oral administration for outpatient care when used appropriately.
Lincomycin capsules and tablets are approved in the EU and US for treating severe Gram-positive infections, including skin, soft tissue, and bone infections. In the EU, brands like Lincocin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on extensive clinical data, with generic formulations available. Both regions require detailed dossiers, including clinical trial data, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert support with regulatory dossiers, compliance, and registration, visit PharmaTradz. We ensure seamless market access for lincomycin formulations, adhering to European and US standards for safe, effective antibacterial therapy.